CoChat

RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis

Open access
Carr, Ryan M., Vorobyev, Denis, Lasho, Terra, Marks, David L., Tolosa, Ezequiel J., Vedder, Alexis, Almada, Luciana L., Yurcheko, Andrey, Padioleau, Ismael, Alver, Bonnie, Coltro, Giacomo, Binder, Moritz, Safgren, Stephanie L., Horn, Isaac, You, Xiaona, Solary, Eric, Balasis, Maria E., Berger, Kurt, Hiebert, James, Witzig, Thomas, Buradkar, Ajinkya, Graf, Temeida, Valent, Peter, Mangaonkar, Abhishek A., Robertson, Keith D., Howard, Matthew T., Kaufmann, Scott H., Pin, Christopher, Fernandez-Zapico, Martin E., Geissler, Klaus, Droin, Nathalie, Padron, Eric, Zhang, Jing, Nikolaev, Sergey, Patnaik, Mrinal M. · 2021 · Nature Communications
Cited by 104

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Proliferative chronic myelomonocytic leukemia (pCMML), an aggressive CMML subtype, is associated with dismal outcomes. RAS pathway mutations, mainly NRASG12D, define the pCMML phenotype as demonstrated by our exome sequencing, progenitor colony assays and a Vav-Cre-NrasG12D mouse model. Further, these mutations promote CMML transformation to acute myeloid leukemia. Using a multiomics platform and biochemical and molecular studies we show that in pCMML RAS pathway mutations are associated with a unique gene expression profile enriched in mitotic kinases such as polo-like kinase 1 (PLK1). PLK1 transcript levels are shown to be regulated by an unmutated lysine methyl-transferase (KMT2A) resulting in increased promoter monomethylation of lysine 4 of histone 3. Pharmacologic inhibition of PLK1 in RAS mutant patient-derived xenografts, demonstrates the utility of personalized biomarker-driven therapeutics in pCMML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23186-w

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 104

Metadata

Authors
Carr, R. M., Vorobyev, D., Lasho, T., Marks, D. L., Tolosa, E. J., Vedder, A., Almada, L. L., Yurcheko, A., Padioleau, I., Alver, B., Coltro, G., Binder, M., Safgren, S. L., Horn, I., You, X., Solary, E., Balasis, M. E., Berger, K., Hiebert, J., Witzig, T., Buradkar, A., Graf, T., Valent, P., Mangaonkar, A. A., Robertson, K. D., Howard, M. T., Kaufmann, S. H., Pin, C., Fernandez-Zapico, M. E., Geissler, K., Droin, N., Padron, E., Zhang, J., Nikolaev, S., & Patnaik, M. M.
Venue
Nature Communications
Published
2021-05-18
Volume
12
Issue
1
Pages
2901-2901
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3161543281
Cited by
104
References
9
FWCI
9.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. https://app.cochat.ai/papers/10.1038/s41467-021-23186-w
The paper
Carr, R. M., Vorobyev, D., Lasho, T., Marks, D. L., Tolosa, E. J., Vedder, A., Almada, L. L., Yurcheko, A., Padioleau, I., Alver, B., Coltro, G., Binder, M., Safgren, S. L., Horn, I., You, X., Solary, E., Balasis, M. E., Berger, K., Hiebert, J., . . . Patnaik, M. M. (2021). RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications. https://doi.org/10.1038/s41467-021-23186-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.